SEC Company Response from Prelude Therapeutics (PRLD) — Dec 15, 2025
Prelude Therapeutics Inc
Date: Dec. 15, 2025 · CIK: 0001678660 · Accession: 0000929638-25-004602
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292048
Letter
Re:
Prelude Therapeutics Inc. 175 Innovation Boulevard Wilmington, Delaware 19805
December 15, 2025
VIA EDGAR TRANSMISSION
Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell, Esq.
Prelude Therapeutics Inc. Registration Statement on Form S-3 Filed December 10, 2025 File No. 333-292048
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Prelude Therapeutics Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-292048), so that such registration statement may become effective at 4:00 p.m. (Washington, D.C. time) on December 16, 2025 or as soon as practicable thereafter.
PRELUDE THERAPEUTICS INC.
By:
/s/ Krishna Vaddi, Ph.D.
Name:
Krishna Vaddi, Ph.D.
Title:
Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm Prelude Therapeutics Inc. 175 Innovation Boulevard Wilmington, Delaware 19805 December 15, 2025 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell, Esq. Re: Prelude Therapeutics Inc. Registration Statement on Form S-3 Filed December 10, 2025 File No. 333-292048 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Prelude Therapeutics Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-292048), so that such registration statement may become effective at 4:00 p.m. (Washington, D.C. time) on December 16, 2025 or as soon as practicable thereafter. PRELUDE THERAPEUTICS INC. By: /s/ Krishna Vaddi, Ph.D. Name: Krishna Vaddi, Ph.D. Title: Chief Executive Officer